Abstract
Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, lenalidomide has emerged as one such option. Lenalidomide demonstrates clinically significant activity with a favorable safety profile as a single agent, as well as in combination therapy. Herein, we review accumulated clinical data on lenalidomide, with particular reference to patients with first-line and relapsed/refractory mantle cell lymphoma, indolent lymphoma, and diffuse large B-cell lymphoma.
Keywords:
Diffuse large B-cell lymphoma; indolent lymphoma; lenalidomide; mantle cell lymphoma; non-Hodgkin lymphoma.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use*
-
Immunomodulation / drug effects
-
Lenalidomide
-
Lymphoma, Non-Hodgkin / diagnosis
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / etiology
-
Lymphoma, Non-Hodgkin / metabolism
-
Signal Transduction / drug effects
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Immunologic Factors
-
Thalidomide
-
Lenalidomide